Lawrence Berkeley Laboratories Begins Using Biolog Phenotype MicroArray Technology in Genomes to Life Project.
HAYWARD, Calif.--(BUSINESS WIRE)--April 27, 2004
Biolog, Inc. announced today that its new Phenotype MicroArray(TM) technology has been installed and begun to be used at Lawrence Berkeley National Laboratory (LBNL) Genomics: GTL Program under a collaborative agreement.
Phenotype MicroArrays (PM) represent a fundamental technology platform, which allows scientists to easily and efficiently test hundreds to thousands of cellular traits simultaneously. The technology has the promise of determining cellular phenotypic expression in many areas of research. The two most important near term applications are using PMs to determine the effect of genetic changes on cells and to determine the effect of drugs on cells.
The LBNL researchers will use the PM technology to understand and characterize phenotypes of different strains of bacteria, specifically focused on strains of Desulfovibrio vulgaris. The phenotypic data derived from these experiments will be interpreted in conjunction with comparative genomic and microarray experiments being done at Lawrence Berkeley National Laboratory for rapid deduction of stress response pathways in metal and radionuclide bacteria.
Terry Hazen, the LBNL senior scientist leading the phenotype microarray analyses said, "We hope to be able to complement our existing genome sequencing, bioinformatic and expression microarray capabilities with Biolog's phenotype microarray technology to further our understanding of this microbes function."
"In our own laboratories, we are demonstrating that the PM phenotypic data alone can provide invaluable information about how and where genes are expressing themselves in this cell line. It is our hope that by linking the PM results to gene expression data, we can efficiently identify how genes are regulating various cellular pathways in these target cells," said, Barry Bochner, Vice President of R&D for Biolog, Inc.
Biolog has installed their proprietary OmniLog(TM) System for high-throughput kinetic analysis of the PM panels at LBNL. The Phenotype MicroArray panels are sets of approximately 2,000 cellular assays that enable comparative analyses of a variety of metabolic and drug sensitivity changes in cells. LBNL will initially be testing bacterial strains. Mutant strains will be analyzed for phenotypic changes using the PM technology and results will then be compared to the phenotypes of the normal cell line. They will then integrate this with the transcriptomics, proteomics, and metabolomics being done for stressors for each strain to provide a unique definition and resolution of cell processes.
Biolog has an active technology-placement program to use the current generation of PMs for research using bacterial and fungal model cell lines. The company is developing similar arrays for use with mammalian cell lines.
This work at Lawrence Berkeley National Laboratory research institute is being funded by the U.S. Department of Energy, Office of Biological and Environmental Research, Genomics: GTL Program whose primary research interests are in structural, functional and comparative analysis of genomes and gene products from a wide variety of organisms affecting the environment. Desulfovibrio vulgaris, a sulfate-reducing bacteria, is one of the key organisms responsible for metal reduction in the environment.
Biolog, a privately held company based in Hayward, CA, is a pioneer in the development of powerful new cell analysis tools for solving critical problems in clinical, pharmaceutical, and biotechnology research and development. The company's Phenotype MicroArray technology and OmniLog PM System can be used in the discovery and development of new drugs as well as bioactive agents for animal and plant applications. Further information can be obtained at the company's website, www.biolog.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 27, 2004|
|Previous Article:||EA to Return Fans to Middle-earth in the Lord of the Rings, the Third Age Roleplaying Game.|
|Next Article:||Navigant International--FLYR--Reports Q1 EBITDA and EPS Ahead of Guidance.|